On November 27, 2023, a General Assembly meeting of stakeholders of the Latvian Medicines Verification Organisation (LZVO) was held, where the strategy and budget for 2024 were approved.
The General Assembly also approved the fixed annual flat fee for the year 2024 for the marketing authorisation holders (MAHs), including parallel importers and parallel distributors of medicines in the territory of Latvia, in accordance with the financing policy for the maintenance and development of the Latvian Medicines Verification System.
Despite changes in the economic growth rates in Europe and the increasing costs of many suppliers and service providers, LZVO has maintained a fixed annual fee of 3000 EUR for the second consecutive year for each MAH. Using the closed section of the customer portal, on November 28th, LZVO informed all MAH’s about the fixed annual fee for the upcoming year.
In case of questions about the annual flat fee or other current events MAH representatives are welcomed to contact LZVO by writing to [email protected].